Drug intelligence / Profile preview

evorpacept + pembrolizumab + doxorubicin

Development stage: Unknown
Lead developer: ALX Oncology
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination therapy regimen consists of evorpacept (ALX148), pembrolizumab, and pegylated liposomal doxorubicin (PLD). It is currently being evaluated in a Phase II clinical trial for the treatment of recurrent platinum-resistant ovarian cancer. Evorpacept is a next-generation CD47 blocker designed as a fusion protein that binds CD47 with high affinity while utilizing an inactive human immunoglobulin Fc region to minimize hematologic side effects. Pembrolizumab is a programmed cell death protein 1 (PD-1) inhibitor that enhances T-cell mediated anti-tumor activity. Pegylated liposomal doxorubicin is a cytotoxic chemotherapy agent that inhibits DNA topoisomerase II. The combination aims to leverage the synergy between innate immune activation (via CD47 blockade), adaptive immune checkpoint inhibition (via PD-1 blockade), and direct cytotoxic tumor cell killing to overcome resistance in ovarian cancer.

Brand names: KeytrudaDoxilLipodox
Other names: ALX148 + pembrolizumab + pegylated liposomal doxorubicinevorpacept + pembrolizumab + pegylated liposomal doxorubicin

Targets

CD47 (Cluster of Differentiation 47)PDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on evorpacept + pembrolizumab + doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evorpacept + pembrolizumab + doxorubicin.

Explore the full profile